India Pharma Outlook Team | Thursday, 31 March 2022
BioNTech said on Wednesday it would extend an ongoing clinical trial programme to produce new vaccines and patterns of administration for better protection against the dominant Omicron coronavirus variant.
The addition of cohorts to a trial programme initially unveiled in January comes as global infection are on the rise and protection against infection from its established Comirnaty vaccine, co-developed with Pfizer, has waned.
Thanks to 10.3 billion euros in net income in 2021, the German biotech company plans to spend between 1.4 billion and 1.5 billion euros on research and development this year. It also plans to buy back up to $1.5 billion worth of shares over two years and pay a special dividend of 486 million euro in total, or 2 euros per share. It reiterated its 2022 vaccine revenue of between 13 billion and 17 billion euros.
, CDSCO.jpg)
